Generic Name and Formulations:
Dextranomer microspheres 50mg/mL viscous gel in stabilized hyaluronic acid 15mg/mL carrier gel; implant for submucosal inj.
Bausch Health Companies Inc.
Indications for DEFLUX:
Vesicoureteral reflux (VUR) grades II–IV in children.
<1yr: not recommended. ≥1yr: see literature. Must use Deflux metal needle for administration. Inject submucosally in urinary bladder near the ureteral orifice.
Non-functional kidney. Hutch diverticulum. Ureterocele. Active voiding dysfunction. Ongoing UTI.
Do not inject intravascularly. Must be administered by qualified surgeon experienced in the use of cystoscope and trained in subureteric injection procedures. Use of >6mL (3mL at each ureteral orifice) at same treatment session: not recommended. Treatment of duplex systems has not been studied. Ureters with grossly dilated orifices. Infection and bleeding risks associated with cystoscopic procedure.
UTI, ureteral dilatation, nausea, vomiting, abdominal pain.
Single-use syringe (1mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML